3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioma
1
Glioblastoma
1
Brain Neoplasms
1
Interventions
pembrolizumab
185
Carboplatin
131
Paclitaxel
123
Gemcitabine
122
Docetaxel
97
Cyclophosphamide
89
Nivolumab
88
Cisplatin
87
Rituximab
71
Dexamethasone
68
Pemetrexed
65
Bevacizumab
65
Capecitabine
60
atezolizumab
55
fludarabine
49
Fluorouracil
49
Azacitidine
49
130-nm albumin-bound paclitaxel
43
Irinotecan
42
venetoclax
41
Trastuzumab
41
Cetuximab
40
Leucovorin
37
Ipilimumab
36
Erlotinib Hydrochloride
35
Oxaliplatin
32
Fulvestrant
32
Cytarabine
32
avelumab
31
Albumin-Bound Paclitaxel
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
INDUSTRY
×
Dianhydrogalactitol
×
Clear all
NCT03149575
2025-09-04
STAR-3
Kintara Therapeutics, Inc.
Phase 3
Terminated
2 enrolled